Risk-based monitoring has attracted the support of a diverse group of organisations in recent years.

Regulators have released guidance encouraging the use of risk-based approaches to clinical trial quality, while vendors have created technologies to support such methods and large pharmaceutical companies have pooled their resources to drive adoption. Yet, despite this flurry of activity, the industry has overlooked a potentially useful source of real-time and historical data.

Download this free white paper to find out more.